Oxford BioMedica notes acceptance by FDA of a Biologics License Application (BLA) filing for CTL019
Oxford, UK – 30 March 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, is pleased to note the announcement by Novartis…